Report cover image

Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027

Publisher Arizton Advisory and Intelligence
Published Jan 25, 2022
Length 292 Pages
SKU # ARZ16941032

Description

Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Cell and Gene Therapy Market Report

The cell and gene therapy market size was valued at USD 4.99 billion in 2021 and is expected to reach USD 36.92 billion by 2027, growing at a CAGR of 39.62 % during the forecast period

The following factors are likely to contribute to the growth of the cell and gene therapy market –
  • Merger & Acquisition
  • Expansion of Manufacturing Plants & Technological Advancement
  • Expanding Application for Cell & Gene Therapies
  • Growing Demand for CAR T- Cell Therapies
  • New Products Approvals & Increasing Pipeline Products
In the cell and gene therapy field, gene therapy gathered the pace last from 2 decades because of the discovery of several genes responsible for mutation in various diseases. The advancement in the cell & gene therapy field and innovative technologies give the new era for biological therapeutics. Also, PRIME Designation and marketing authorization for products provide a new opportunity for the manufacturer's financing and revenue generation.

KEY HIGHLIGHTS
  • As per the American Society of Cell + Gene Therapy report in 2021, increasing the number of cellular and gene therapy products, application rate and products in clinical trials drive the market growth.
  • As per the Dive Biopharma report 2021, biotech companies who actively engaged in regenerative medicines and therapies reported USD 14 billion funding only in six months of 2021 which was reported to be USD 19.9 billion for the overall year.
CELL AND GENE THERAPY MARKET SEGMENTS

Cell and gene therapy market is segmented on the basis of-
  • Therapy type
  • Application
  • End-users
  • Geography
CELL AND GENE THERAPY MARKET SEGMENTATION
  • Increasing application of gene therapies in diseases diagnosis and rapidly growing new drugs applications will give new market space in upcoming years. In 2020, around USD 2.3 billion funding was reported only from private companies for gene therapies. By 2025, the FDA is expected to approve 10−20 products each year, driving the global cell and gene therapy manufacturing market.
  • In 2020, Medicine in Development Report 2020, around 176 products were reported in cancer therapies in development procedures.
Market segmentation by Therapy Type
  • Gene Therapy
  • Cell Therapy
Market segmentation by Application
  • Oncology
  • Genetic Disorders
  • Dermatology Disorders
  • Musculoskeletal Disorders
  • Others
Market segmentation by End-Users
  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • Others
GEOGRAPHICAL OUTLOOK
  • North America: High economic status and high expenditure on healthcare services drive the cell and gene therapy market in North America. National Health Institutes, industries, academic institutes, and hospitals are the significant contributors of sponsorship and financial funding for cell and gene therapy products.
  • Europe: The increasing funding for cell and gene therapy drives the cell and gene therapy market growth consistently in Europe. Around USD 2.6 billion financings were reported in Europe for CGTs in 2020, which increased by 103% compared to previous years. In the cell therapy segment, USD 1.8 billion and in gene therapy, USD 2.3 billion funding accounted in 2020, which increased by 196% and 111% growth respectively
Market segmentation by Geography
  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • APAC
  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • South Africa
  • Israel
VENDOR LANDSCAPE
  • The key players in the cell and gene therapy market are Gilead Sciences, Novartis, Smith Nephew, Amgen, Organogenesis, Roche (Spark Therapeutics), Dendreon, Vericel, and Bristol-Myers Squibb Company.
  • An increasing number of mergers and acquisitions gives new potential to market growth. Gilead Sciences acquired Kite Pharma in 2020. Also, Novartis acquired Avexis in 2018, and Smith & Nephew acquired Osiris Therapeutics.
Key Vendors
  • Gilead sciences
  • Novartis
  • Smith Nephew (Osiris Therapeutic)
  • Amgen
  • Organogenesis
  • Roche (Spark Therapeutics)
  • Dendreon
  • Vericel
  • Bristol-Myers Squibb
Other Prominent Vendors
  • Abeona Therapeutics
  • APAC Biotech Pvt Ltd
  • Alnylam
  • Allovir
  • Tego Sciences
  • Avita Medical
  • Anterogen
  • AnGes Inc.
  • BioSolution Co. Ltd.
  • Cheisi Farmaceutici
  • CollPlant
  • CO.DON
  • Corestem
  • Bluebird Bio Inc
  • Biosolution
  • Stempeutics Research
  • GC Cell
  • Sanofi
  • Gensight biologics
  • Human Stem Cells Institute
  • JW CreaGene Co. Ltd
  • JCR Pharmaceuticals
  • Japan Tissue Engineering (J-TEC)
  • Kolon TissueGene
  • Medipost
  • MolMed
  • Nuvasive Inc.
  • Nipro Corporation
  • Orchard Therapeutics
  • Orthocell
  • Pfizer
  • Pharmicell
  • Sibiono Genetech
  • Shanghai Sunway Biotech
  • RMS Regenerative Medical System
  • Takeda Pharmaceuticals Company
  • Terumo
Upcoming Vendors
  • Biomarin Pharmaceutical
  • Bellicum Pharmaceutical
  • Castle Creek Biosciences Inc
  • Libella Gene Therapeutics
  • CARsgen Therapeutics
  • Hrain Biotechnology Co. Ltd
  • Helixmith
  • Krystal Biotech Inc.
  • JW Therapeutic
  • Poseida Therapeutics
KEY QUESTIONS ANSWERED:

1. How big is the global cell & gene therapy market?

2. What are the latest trends in the cell & gene therapy market?

3. Who are the key players in the cell & gene therapy market?

4. Which region has the highest share in the cell & gene therapy market?

5. Who are the end-users of the cell & gene therapy market?

Table of Contents

292 Pages
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.1.1 Cell & Gene Therapy Approved Products 2020−2021
7.2 Cell & Gene Therapy Phase-III Products
7.3 Road Map of Cell & Gene Therapy
8 Market Opportunities & Trends
8.1 Rising Number of Mergers & Acquisitions
8.2 Expansion of CGT Manufacturing Plants
8.3 Expanding Applications for Cell & Gene Therapies
8.4 Growing Demand for Car T-Cell Therapies
9 Market Growth Enablers
9.1 New Product Approvals & Increasing Pipeline of Products
9.2 Prime Designation & Funding Support For CGT
9.3 Rising Use of CGT Products for Disease Care
9.4 Increasing Use of CGT Products for Disease Treatment
10 Market Restraints
10.1 High Cost of Cell & Gene Therapies
10.2 Ethical Issues Regarding Genetical Material
10.3 Stringent Regulation for CGT Approvals
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry
12 Therapy
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Gene Therapy
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Cell Therapy
12.4.1 Market Overview
12.4.2 Market Size & Forecast
13 Application
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Oncology
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Genetic Disorders
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Dermatology
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Musculoskeletal Diseases
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.7 Other Diseases
13.7.1 Market Overview
13.7.2 Market Size & Forecast
14 End-User
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Cancer Care Centers
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Wound Care Centers
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 Other End-Users
14.6.1 Market Overview
14.6.2 Market Size & Forecast
15 Geography
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
15.2.1 Global Cell & Gene Therapy Market by Geography
16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US: Market Size & Forecast
16.3.2 Canada: Market Size & Forecast
17 Europe
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Germany: Market Size & Forecast
17.3.2 France: Market Size & Forecast
17.3.3 UK: Market Size & Forecast
17.3.4 Spain: Market Size & Forecast
17.3.5 Italy: Market Size & Forecast
18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Japan: Market Size & Forecast
18.3.2 China: Market Size & Forecast
18.3.3 South Korea: Market Size & Forecast
18.3.4 Australia: Market Size & Forecast
18.3.5 India: Market Size & Forecast
19 Latin America
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Brazil: Market Size & Forecast
19.3.2 Mexico: Market Size & Forecast
20 Middle East & Africa
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
20.3.1 Turkey: Market Size & Forecast
20.3.2 Saudi Arabia: Market Size & Forecast
20.3.3 UAE: Market Size & Forecast
20.3.4 South Africa: Market Size & Forecast
20.3.5 Israel: Market Size & Forecast
21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
22 Key Company Profiles
22.1 GILEAD SCIENCES
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 NOVARTIS
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 SMITH NEPHEW (OSIRIS THERAPEUTICS)
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 AMGEN
22.4.1 Business Overview
22.4.2 Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
22.5 ORGANOGENESIS
22.5.1 Business Overview
22.5.2 Product Offerings
22.5.3 Key Strategies
22.5.4 Key Strengths
22.5.5 Key Opportunities
22.6 ROCHE (SPARK THERAPEUTICS)
22.6.1 Business Overview
22.6.2 Product Offerings
22.6.3 Key Strategies
22.6.4 Key Strengths
22.6.5 Key Opportunities
22.7 DENDREON
22.7.1 Business Overview
22.7.2 Product Offerings
22.7.3 Key Strategies
22.7.4 Key Strengths
22.7.5 Key Opportunities
22.8 VERICEL
22.8.1 Business Overview
22.8.2 Product Offerings
22.8.3 Key Strategies
22.8.4 Key Strengths
22.8.5 Key Opportunities
22.9 BRISTOL MEYER SQUIBB
22.9.1 Business Overview
22.9.2 Product Offerings
22.9.3 Key Strategies
22.9.4 Key Strengths
22.9.5 Key Opportunities
23 Other Prominent Vendors
23.1 ABEONA THERAPEUTICS
23.1.1 Business Overview
23.1.2 Product Offerings
23.2 APAC BIOTECH PVT LTD
23.2.1 Business Overview
23.2.2 Product Offerings
23.3 ALNYLAM
23.3.1 Business Overview
23.3.2 Product Offerings
23.4 ALLOVIR
23.4.1 Business Overview
23.4.2 Product Offerings
23.5 TEGO SCIENCES
23.5.1 Business Overview
23.5.2 Product Offerings
23.6 AVITA MEDICAL
23.6.1 Business Overview
23.6.2 Product Offerings
23.7 ANTEROGEN
23.7.1 Business Overview
23.7.2 Product Offerings
23.8 ANGES INC
23.8.1 Business Overview
23.8.2 Product Offerings
23.9 BIOSOLUTION CO. LTD
23.9.1 Business Overview
23.9.2 Product Offerings
23.10 CHEISI FARMACEUTICI
23.10.1 Business Overview
23.10.2 Product Offerings
23.11 COLLPLANT
23.11.1 Business Overview
23.11.2 Product Offerings
23.12 CO.DON
23.12.1 Business Overview
23.12.2 Product Offerings
23.13 CORESTEM
23.13.1 Business Overview
23.14 BLUEBIRD BIO INC
23.14.1 Business Overview
23.14.2 Product Offerings
23.15 STEMPEUTICS RESEARCH
23.15.1 Business Overview
23.15.2 Product Offerings
23.16 Gc Cell
23.16.1 Product Offerings
23.17 SANOFI
23.17.1 Business Overview
23.17.2 Product Offerings
23.18 GENSIGHT BIOLOGICS
23.18.1 Business Overview
23.18.2 Product Offerings
23.19 HUMAN STEM CELL INSTITUTE
23.19.1 Business Overview
23.19.2 Product Offerings
23.20 JW CREAGENE CO. LTD
23.20.1 Business Overview
23.20.2 Products Offerings
23.21 JCR PHARMACEUTICALS
23.21.1 Business Overview
23.21.2 Products Offerings
23.22 JAPAN TISSUE ENGINEERING (J-TEC)
23.22.1 Business Overview
23.22.2 Product Offerings
23.23 KOLON TISSUEGENE
23.23.1 Business Overview
23.23.2 Product Offerings
23.24 MEDIPOST
23.24.1 Business Overview
23.24.2 Product Offerings
23.25 MOLMED
23.25.1 Business Overview
23.25.2 Product Offerings
23.26 NUVASIVE INC
23.26.1 Business Overview
23.26.2 Product Offerings
23.27 NIPRO CORPORATION
23.27.1 Business Overview
23.27.2 Product Offerings
23.28 ORCHARD THERAPEUTICS
23.28.1 Business Overview
23.28.2 Product Offerings
23.29 ORTHOCELL
23.29.1 Business Overview
23.29.2 Product Offerings
23.30 PFIZER
23.30.1 Business Overview
23.30.2 Product Offerings
23.31 PHARMICELL
23.31.1 Business Overview
23.31.2 Product Offerings
23.32 SIBIONO GENETECH
23.32.1 Business Overview
23.32.2 Product Offerings
23.33 SHANGHAI SUNWAY BIOTECH
23.33.1 Business Overview
23.33.2 Product Offerings
23.34 RMS REGENERATIVE MEDICAL SYSTEM
23.34.1 Business Overview
23.34.2 Product Offerings
23.35 TAKEDA PHARMACEUTICALS COMPANY
23.35.1 Business Overview
23.35.2 Product Offerings
23.36 TERUMO
23.36.1 Business Overview
23.36.2 Product Offerings
24 Upcoming Market Vendors
24.1 BIOMARIN PHARMACEUTICALS
24.1.1 Business Overview
24.1.2 Product Offerings
24.2 BELLICUM PHARMACEUTICALS
24.2.1 Business Overview
24.2.2 Product Offering
24.3 CASTLE CREEK BIOSCIENCES INC.
24.3.1 Business Overview
24.3.2 Product Offerings
24.4 LIBELLA GENE THERAPEUTICS
24.4.1 Business Overview
24.4.2 Product Offerings
24.5 CARSGEN THERAPEUTICS
24.5.1 Business Overview
24.5.2 Product Offerings
24.6 HRAIN BIOTECHNOLOGY CO. LTD.
24.6.1 Business Overview
24.6.2 Product Offerings
24.7 HELIXMITH
24.7.1 Business Overview
24.7.2 Product Offerings
24.8 KRYSTAL BIOTECH INC.
24.8.1 Business Overview
24.8.2 Product Offerings
24.9 JW THERAPEUTICS
24.9.1 Business Overview
24.9.2 Product Offerings
24.10 POSEIDA THERAPEUTICS
24.10.1 Business Overview
24.10.2 Product Offerings
25 Report Summary
25.1 Key Takeaways
25.2 Strategic Recommendations
26 Quantitative Summary
26.1 Market by Geography
26.1.1 Global Cell & Gene Therapy Market by Geography
26.1.2 Global Cell & Gene Therapy Market by Therapy Type
26.1.3 Global Cell & Gene Therapy Market by Diseases
26.1.4 Global Cell & Gene Therapy Market by End-User
27 Appendix
27.1 Abbreviations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us